Analysis Tools
hematopoietic system
|
• visibly anemic by 8 days after the first tamoxifen injection
• severe iron deficient anemia develops by 6 - 7 weeks after the start of tamoxifen treatment
|
|
• by 6 - 7 weeks after the start of tamoxifen treatment, average hematocrit is 11.2 +/- 1.6% compared to 45.3 +/- 5.9% in controls without the cre transgene
• parenteral treatment with iron dextran restores hematocrits in tamoxifen treated mice to levels similar to control mice that do not carry the cre transgene
|
|
• by 6 - 7 weeks after the start of tamoxifen treatment, average hemoglobin concentration is 2.8 +/- 0.6 g/dl compared to 13.8 +/- 1.8 g/dl in controls without the cre transgene
|
|
• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment
|
homeostasis/metabolism
|
• significant iron accumulation in duodenal enterocytes after tamoxifen treatment
|
|
• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment
|
|
• a 5.5-fold decrease in hepatic nonheme iron is seen after tamoxifen treatment
|
digestive/alimentary system
|
• significant iron accumulation in duodenal enterocytes after tamoxifen treatment
|
immune system
|
• a 4.7-fold decrease in splenic nonheme iron is seen after tamoxifen treatment
|
liver/biliary system
|
• a 5.5-fold decrease in hepatic nonheme iron is seen after tamoxifen treatment
|
